secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001104659-25-026392
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma tivoxavir marboxil shows 100% survival in H5N1 rodent model; Phase 1 PK positive
--------------------------------------------------------------------------------

- 100% of TXM-treated mice survived lethal H5N1 challenge; all untreated controls died by study day 6.
- Single 240 mg dose maintained plasma levels at EC90 for ~25 days; well tolerated up to 480 mg in Phase 1.
- TXM exhibited sub-nanomolar EC50 against circulating 2022-2023 H5N1 strains and baloxavir-resistant viruses.
- Investor call scheduled for March 31, 2025 at 10:00 AM ET to review antiviral programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/0001104659-25-026392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/tm259925d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer